Argentyna - hiszpański - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

abbott laboratories argentina s.a. - aceite de canola; vitamina k1 - solucion - aceite de canola 1.1 g %; vitamina k1 9.8 mcg %

Unia Europejska - hiszpański - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - inmunosupresores - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. el tratamiento de graves, activa y progresiva de la artritis reumatoide en adultos no tratados previamente con metotrexato. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita reduce la tasa de progresión del daño articular medido por rayos x y de mejora de la función física, cuando se administra en combinación con metotrexato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita puede ser administrado como monoterapia en caso de intolerancia al metotrexato o cuando el tratamiento continuado con metotrexato no es la adecuada (para la eficacia en monoterapia véase la sección 5. adalimumab no ha sido estudiado en pacientes menores de 2 años. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita reduce la tasa de progresión de periféricos daño articular medido por rayos x en pacientes con poliarticular simétrica subtipos de la enfermedad (ver sección 5. 1) y mejora la función física. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 y 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Hiszpania - hiszpański - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - meloxicam - soluciÓn para pulverizaciÓn bucal - excipientes: alcohol etilico (etanol), policarbofilo, acido borico, cloruro potasico, acido clorhidrico, hidroxido de sodio (e-524), agua purificada - meloxicam - perros

Hiszpania - hiszpański - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - meloxicam - soluciÓn para pulverizaciÓn bucal - excipientes: alcohol etilico (etanol), policarbofilo, acido borico, cloruro potasico, acido clorhidrico, hidroxido de sodio (e-524), agua purificada - meloxicam - perros

Unia Europejska - hiszpański - EMA (European Medicines Agency)

zoetis belgium sa - meloxicam - oxicams - perros - alivio de la inflamación y el dolor en los trastornos musculoesqueléticos agudos y crónicos en perros.

Hiszpania - hiszpański - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - meloxicam - soluciÓn para pulverizaciÓn bucal - excipientes: alcohol etilico (etanol), policarbofilo, acido borico, cloruro potasico, acido clorhidrico, hidroxido de sodio (e-524), agua purificada - meloxicam - perros

Hiszpania - hiszpański - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

alcon cusi, s.a. - retinol palmitato; nicotinato tocoferol - cÁpsula blanda - 25.000 ui/230 mg - retinol palmitato 25000 ui; nicotinato tocoferol 230 ui - vitaminas, otras combinaciones

Hiszpania - hiszpański - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pharbio medical international ab - acido cichorico, echinacea purpurea - excipientes: - fÁrmacos usados en desÓrdenes adictivos - fÁrmacos usados en desÓrdenes adictivos - fÁrmacos usados en desÓrdenes adictivos

Peru - hiszpański - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

tecnofarma s.a. - droguerÍa - adalimumab - solucion inyectable - 20mg/0.4ml - por jeringa precargada ml - - adalimumab

Peru - hiszpański - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

tecnofarma s.a. - droguerÍa - adalimumab - solucion inyectable - 40mg/0.8ml - por jeringa precargada ml - - adalimumab